Abstract:Objectives: The aim of this study was to test the hypothesis that narrowing the landing zone using commercially available endografts would enable transcatheter pulmonary valve replacement (TPVR) using commercially available transcatheter heart valves. Background: TPVR is challenging in an outsized native or patch-repaired right ventricular outflow tract (RVOT). Downsizing the RVOT for TPVR is currently possible only using investigational devices. In patients ineligible because of excessive RVOT size, TPVR landing zones were created using commercially available endografts. Methods: Consecutive patients with native or patch-repaired RVOTs and high or prohibitive surgical risk were reviewed, and this report describes the authors' experience with endograft-facilitated TPVR (EF-TPVR) offered to patients ineligible for investigational or commercial devices. All EF-TPVR patients were surgery ineligible, with symptomatic, severe pulmonary insufficiency, enlarged RVOTs, and severe right ventricular (RV) enlargement (>150 ml/m2). TPVR and surgical pulmonary valve replacement (SPVR) were compared in patients with less severe RV enlargement. Results: Fourteen patients had large RVOTs unsuitable for conventional TPVR; 6 patients (1 surgery ineligible) received investigational devices, and 8 otherwise ineligible patients underwent compassionate EF-TPVR (n = 5 with tetralogy of Fallot). Three strategies were applied on the basis of progressively larger RVOT size: single-barrel, in situ fenestrated, and double-barrel endografts as required to anchor 1 (single-barrel and fenestrated) or 2 (double-barrel) transcatheter heart valves. All were technically successful, without procedure-related, 30-day, or in-hospital deaths. Two late complications (stent obstruction and embolization) were treated percutaneously. One patient died of ventricular tachycardia 36 days after EF-TPVR. Compared with 48 SPVRs, RV enlargement was greater, but 30-day and 1-year mortality and readmission were no different. The mean transvalvular pressure gradient was lower after EF-TPVR (3.8 ± 0.8 mm Hg vs. 10.7 ± 4.1 mm Hg; p < 0.001; 30 days). More than mild pulmonary insufficiency was equivalent in both (EF-TPVR 0.0% [n = 0 of 8] vs. SPVR 4.3% [n = 1 of 43]; p = 1.00; 30 days). Conclusions: EF-TPVR may be an alternative for patients with pulmonic insufficiency and enlarged RVOTs ineligible for other therapies.

[Preliminary Experience of Transcatheter Pulmonary Valve Replacement Using Domestic Balloon-Expandable Valve].

First Two Cases of Transcatheter Aortic Valve Replacement with Lotus Valve System in China

Transcatheter Aortic Valve Implantation with Balloon-Expandable Valve: Early Experience from China.

[Preliminary Clinical Experience of the Novel Transcatheter Aortic Valve System Prizvalve® for the Treatment of Severe Aortic Stenosis].

Early Clinical Experience with a Novel Self‐expanding Percutaneous Stent‐valve in the Native Right Ventricular Outflow Tract

Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry

Transthoracic Salus Valve Feasibility Study: Short-Term Outcomes of a Transcatheter Self-Expandable Pulmonary Valve

Severe Symptomatic Bicuspid and Tricuspid Aortic Stenosis in China: Characteristics and Outcomes of Transcatheter Aortic Valve Replacement with the Venus-A Valve (vol 2, pg 60, 2018)

Transcatheter Aortic Valve Implantation with the Self-Expandable Venus A-Valve and CoreValve Devices: Preliminary Experiences in China.

Initial experience of percutaneous pulmonary valve implantation using self-expanding valve

2024 Statement from Asia expert operators on transcatheter pulmonary valve replacement

Aortic Valve Replacement Via Transfemoral Balloon Dilation: an Initial Experience

Outcomes of Self-Expanding Transcatheter Pulmonary Valves: Extended Follow-Up of a Prospective Trial

The Clinical Trial Outcomes of Med-Zenith PT-Valve in the Treatment of Patients with Severe Pulmonary Regurgitation

Clinical practice and prognosis of emergent transcatheter aortic valve replacement

Multicenter Comparison of Percutaneous and Surgical Pulmonary Valve Replacement in Large RVOT.

Treatment of Severe Pulmonary Regurgitation in Enlarged Native Right Ventricular Outflow Tracts: Transcatheter Pulmonary Valve Replacement with Three-Dimensional Printing Guidance.

Single-Barrel, Double-Barrel, and Fenestrated Endografts to Facilitate Transcatheter Pulmonary Valve Replacement in Large RVOT

The First 10 Balloon Dilated Aortic Valve Replacement Patients in China

A Self-Expanding Percutaneous Valve for Patients with Pulmonary Regurgitation and an Enlarged Native Right Ventricular Outflow Tract: One-Year Results

Transcatheter Aortic Valve Implantation: Preliminary Experience in West China Hospital